Journal of the American Society of Nephrology, Vol 4, 1522-1530, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective

RH Sterns, JD Cappuccio, SM Silver and EP Cohen
University of Rochester School of Medicine, Rochester General Hospital, Department of Medicine, NY.

Severe, symptomatic hyponatremia is often treated urgently to increase the serum sodium to 120 to 130 mmol/L. Recently, this approach has been challenged by evidence linking "rapid correction" (> 12 mmol/L per day) to demyelinating brain lesions. However, the relative risks of persistent, severe hyponatremia and iatrogenic injury have not been well quantified. Data were sought on patients with serum sodium levels < or = 105 mmol/L from the membership of the American Society of Nephrology. Respondents were given a report form asking specific questions regarding the cause of hyponatremia, presenting symptoms, rate of correction, and neurologic sequelae. Data on 56 patients were analyzed. Fourteen developed posttherapeutic complications (10 permanent, 4 transient) after correction to a serum sodium > 120 mmol/L. Eleven of these 14 patients (including 3 with documented central pontine myelinolysis) had a biphasic course in which neurologic findings initially improved and then worsened on the second to sixth day. Posttherapeutic complications were not explained by age, sex, alcoholism, presenting symptoms, or hypoxic episodes. Increased chronicity of hyponatremia and a high rate of correction in the first 48 h of treatment were significantly associated with complications. No neurologic complications were observed among patients corrected by < 12 mmol/L per 24 h or by < 18 mmol/L per 48 h or in whom the average rate of correction to a serum sodium of 120 mmol/L was < or = 0.55 mmol/L per hour. It was concluded that patients with severe chronic hyponatremia are most likely to avoid neurologic complications when their electrolyte disturbance is corrected slowly.

This article has been cited by other articles:

				R. W. Lehrich and A. Greenberg When Is It Appropriate to Use Vasopressin Receptor Antagonists? J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1054 - 1058. [Abstract] [Full Text] [PDF]

				S. J. Whitmire Nutrition-Focused Evaluation and Management of Dysnatremias Nutr Clin Pract, April 1, 2008; 23(2): 108 - 121. [Abstract] [Full Text] [PDF]

				A. Perianayagam, R. H. Sterns, S. M. Silver, M. Grieff, R. Mayo, J. Hix, and R. Kouides DDAVP Is Effective in Preventing and Reversing Inadvertent Overcorrection of Hyponatremia Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 331 - 336. [Abstract] [Full Text] [PDF]

				H. K. Mohmand, D. Issa, Z. Ahmad, J. D. Cappuccio, R. W. Kouides, and R. H. Sterns Hypertonic Saline for Hyponatremia: Risk of Inadvertent Overcorrection Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1110 - 1117. [Abstract] [Full Text] [PDF]

				T. Berl The Adrogue-Madias Formula Revisited Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1098 - 1099. [Full Text] [PDF]

				G. Decaux V2-antagonists for the treatment of hyponatraemia Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1853 - 1855. [Full Text] [PDF]

				M. J Cawley Hyponatremia: Current Treatment Strategies and the Role of Vasopressin Antagonists Ann. Pharmacother., May 1, 2007; 41(5): 840 - 850. [Abstract] [Full Text] [PDF]

				M. A. Munger New agents for managing hyponatremia in hospitalized patients Am. J. Health Syst. Pharm., February 1, 2007; 64(3): 253 - 265. [Abstract] [Full Text] [PDF]

				A. Soupart, P. Gross, J.-J. Legros, S. Alfoldi, D. Annane, H. M. Heshmati, and G. Decaux Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1154 - 1160. [Abstract] [Full Text] [PDF]

				G. Liamis, M. Kalogirou, V. Saugos, and M. Elisaf Therapeutic approach in patients with dysnatraemias Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1564 - 1569. [Abstract] [Full Text] [PDF]

				M. D. Kraft, I. F. Btaiche, G. S. Sacks, and K. A. Kudsk Treatment of electrolyte disorders in adult patients in the intensive care unit Am. J. Health Syst. Pharm., August 15, 2005; 62(16): 1663 - 1682. [Abstract] [Full Text] [PDF]

				E.J. Hoorn, M.L. Halperin, and R. Zietse Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options QJM, July 1, 2005; 98(7): 529 - 540. [Abstract] [Full Text] [PDF]

				K. E. Yeates, M. Singer, and A. R. Morton Salt and water: a simple approach to hyponatremia Can. Med. Assoc. J., February 3, 2004; 170(3): 365 - 369. [Abstract] [Full Text] [PDF]

				P. GROSS, D. REIMANN, J. HENSCHKOWSKI, and M. DAMIAN Treatment of Severe Hyponatremia: Conventional and Novel Aspects J. Am. Soc. Nephrol., February 1, 2001; 12(90001): 10S - 14. [Abstract] [Full Text]

				H. J. Adrogue and N. E. Madias Hyponatremia N. Engl. J. Med., May 25, 2000; 342(21): 1581 - 1589. [Full Text] [PDF]

				W. D. Brown and J. M. Caruso Extrapontine Myelinolysis With Involvement of the Hippocampus in Three Children With Severe Hypernatremia J Child Neurol, July 1, 1999; 14(7): 428 - 433. [Abstract] [PDF]

				L. Gregorio, C. L. Sutton, and D. A. Lee Central Pontine Myelinolysis in a Previously Healthy 4-Year-Old Child With Acute Rotavirus Gastroenteritis Pediatrics, May 1, 1997; 99(5): 738 - 738. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673